Compare Kaltura Inc (KLTR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Recursion Pharmaceuticals Inc — how do they compare? Kaltura Inc trades at $1.32 (market cap $199.08M), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 10.7× Kaltura Inc's market cap, and Kaltura Inc is more actively traded (175,927 versus 30,789,535). Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KLTR | RXRX | |
|---|---|---|
Market Cap | $199.08M | $2.14B |
Volume | 175,927 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $1.89 | $6.79 |
52-Week Low | $1.08 | $2.84 |
Typical Hold Time | 21 Days | 23 Days |
Enterprise Value | $211.29M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kaltura (KLTR) trades at $1.305, down 1.88% with bearish technical signals. The company shows improving fundamentals with revenue stabilizing around $181M and narrowing losses, though still unprofitable. Recent positive developments include AI platform recognition and major streaming contracts, while valuation metrics remain elevated with P/S of 1.08 and EV/EBITDA of 271.59.
The outlook balances AI growth potential against persistent profitability challenges. Analyst consensus leans positive with 44% buy ratings, but high debt levels and negative cash flow present execution risks. The stock's direction hinges on AI monetization success and path to sustainable profitability.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
